This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Comment: AstraZeneca-Alexion US clearance shows large pharma deals can still avoid deep probes

By Flavia Fortes and Jenna Ebersole ( April 16, 2021, 20:02 GMT | Comment) -- The clearance of AstraZeneca’s proposed acquisition of Alexion by the US Federal Trade Commission shows that large pharmaceutical deals can still escape lengthy investigations in the Biden administration despite promises for more aggressive enforcement. The FTC was able to resolve questions in a 60-day initial review, with early-stage drug overlaps and criticism of the current pharma approach from Democrats failing to prompt a deeper probe.The clearance of AstraZeneca’s proposed acquisition of Alexion by the US Federal Trade Commission shows that large pharmaceutical deals can still escape lengthy scrutiny during the Biden administration despite promises for more aggressive enforcement....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login